This clinical practice guideline from the American Heart Association (AHA) aims to give healthcare providers consistent, clear, and evidence-based guidance for treating patients at risk for atherosclerotic cardiovascular disease (ASCVD)
AHA cholesterol management guideline for healthcare practitioners
American Heart Association (AHA), 2018
This clinical practice guideline from the American Heart Association (AHA) aims to give healthcare
providers consistent, clear, and evidence-based guidance for treating patients at risk for atherosclerotic
cardiovascular disease (ASCVD).
The guidance covers risk assessment, primary and secondary prevention of ASCVD, lifestyle
interventions, statin therapy, and non-statin alternatives and adjuncts. It also includes printable tools to help:
- Assess patients’ risk for ASCVD and the use of tools such as the ASCVD risk calculator
- Understand when and how to prescribe and manage statins and non-statin therapies
- Discuss a patient’s ASCVD risks as well as options for treatment
- Overcome common barriers to treatment
The authors highlight that, for primary prevention of ASCVD, fasting and non-fasting total cholesterol and HDL-C levels have similar prognostic value and associations with CVD outcomes. Therefore, recommendations are to measure either a fasting or a non-fasting plasma lipid profile to estimate ASCVD risk and document baseline LDL-C in adults who are 20 years or older and not on lipid-lowering therapy. Point-of-care lipid testing (and screening), as a result, can be used in place of traditional fasting laboratory lipid tests, where there is potential clinical benefit.
The guidelines can be accessed here.
© 2023 애보트. 판권 소유. 참조된 모든 상표는 Abbott 그룹 회사 또는 해당 소유자의 상표입니다.
The American Diabetes Association standards of care - 2023 guidelines provide recommendations for healthcare providers regarding cardiovascular disease (CVD) and risk management in people with diabetes. The authors highlight that atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are leading causes of morbidity and mortality for people with diabetes, noting that simultaneously addressing cardiovascular (CV) risk factors can con...
American Diabetes Association recommendations for cardiovascular disease in diabetesen지금 액세스
The Kidney Disease: Improving Global Outcomes (KIDGO) 2022 clinical practice guidelines are based on a systematic review of evidence and aim to assist health care professionals with their decision making for people with diabetes and chronic kidney disease (CKD). The authors highlight that by 2045, 784 million people are estimated to have diabetes globally, of whom ≥40% will develop CKD, potentially leading to kidney failure requiring dialysis or ...
KIDGO clinical practice guidelines: diabetes management in chronic kidney diseaseen지금 액세스
The objective of this longitudinal cohort study was to determine the prevalence of chronic kidney disease (CKD) and associated risk factors in a rural South African population. The authors note that infectious and non-communicable disease are a substantial risk for CKD in Africa, but that heterogeneity in assessment and diagnostic criteria hamper the interpretation of prevalence.
Chronic kidney disease prevalence and risks in rural South Africaen지금 액세스